NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
NCT05277753
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
T-Cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL:
Antigen-specific T cells CAR-T/CTL and DCvac
Sponsor
Shenzhen Geno-Immune Medical Institute